Memantine plus donepezil improves physical and mental health in people with Alzheimer's disease.
نویسنده
چکیده
Outcomes: Primary outcomes: cognitive dysfunction (Severe Impairment Battery (SIB)); activities of daily living (modified 19 item Alzheimer’s disease Co-operative Study-Activities of Daily Living Inventory (ADCS-ADL19)). Secondary outcomes: effects of medication (Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus)); frequency and severity of behavioural symptoms (Neuropsychiatric Inventory (NPI)), and cognition, functioning and behaviour (Behavioral Rating Scale for Geriatric Patients (BGP)).
منابع مشابه
Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer's disease.
Study selection and analysis: Eligible studies were randomised controlled trials comparing donepezil versus placebo in people with mild to moderate Alzheimer’s disease (MMSE criteria). Trials were undertaken and completed by 20 December 1999. Exclusions: not stated. Data were extracted for each individual study on the efficacy and safety of donepezil. Meta-analysis was carried out using fixed a...
متن کاملCost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
OBJECTIVE Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. METHODS Cost-effectiveness ...
متن کاملThe Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
Background: Vascular dementia is one of the most common forms of dementia. At now, there is no treatment available to cure vascular dementia or to alter its clinical course. Some studies suggest that some drugs may be useful in controlling symptoms. The aim of this study was to evaluate the effects of donepezil, memantine, rivastigmine and galantamine on mean flow velocity and ...
متن کاملMemantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
CONTEXT Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed. OBJECTIVE To compare the efficacy an...
متن کاملDOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
BACKGROUND Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Evidence-based mental health
دوره 7 3 شماره
صفحات -
تاریخ انتشار 2004